Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab

Next Previous
X
Search
Trial Profile

A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Trastuzumab (Primary) ; Utomilumab (Primary) ; Vinorelbine (Primary) ; Antihistamines; Paracetamol
  • Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms AVIATOR

    • Most Recent Events

    • 07 Dec 2023 According to a Dana-Farber Cancer Institute media release, data from this study were presented by Waks at the San Antonio Breast Cancer Symposium.
    • 07 Dec 2023 Results presented in a Dana-Farber Cancer Institute Media Release.
    • 16 Mar 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top